- Home
- NCRA vs CMMB Comparison
NCRA vs CMMB Comparison
Compare NCRA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCRA
- CMMB
- Stock Information
- Founded
- NCRA 2002
- CMMB 2004
- Country
- NCRA Taiwan
- CMMB Israel
- Employees
- NCRA N/A
- CMMB N/A
- Industry
- NCRA Farming/Seeds/Milling
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- NCRA Consumer Staples
- CMMB Health Care
- Exchange
- NCRA Nasdaq
- CMMB Nasdaq
- Market Cap
- NCRA 14.8M
- CMMB 22.0M
- IPO Year
- NCRA N/A
- CMMB N/A
- Fundamental
- Price
- NCRA $1.02
- CMMB $1.17
- Analyst Decision
- NCRA
- CMMB Strong Buy
- Analyst Count
- NCRA 0
- CMMB 2
- Target Price
- NCRA N/A
- CMMB $8.50
- AVG Volume (30 Days)
- NCRA 33.2K
- CMMB 182.0K
- Earning Date
- NCRA 08-13-2025
- CMMB 08-20-2025
- Dividend Yield
- NCRA N/A
- CMMB N/A
- EPS Growth
- NCRA N/A
- CMMB N/A
- EPS
- NCRA N/A
- CMMB N/A
- Revenue
- NCRA $16,647,379.00
- CMMB N/A
- Revenue This Year
- NCRA N/A
- CMMB N/A
- Revenue Next Year
- NCRA N/A
- CMMB N/A
- P/E Ratio
- NCRA N/A
- CMMB N/A
- Revenue Growth
- NCRA N/A
- CMMB N/A
- 52 Week Low
- NCRA $0.70
- CMMB $0.87
- 52 Week High
- NCRA $2.09
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- NCRA 49.20
- CMMB 42.36
- Support Level
- NCRA $0.97
- CMMB $1.17
- Resistance Level
- NCRA $1.05
- CMMB $1.23
- Average True Range (ATR)
- NCRA 0.05
- CMMB 0.05
- MACD
- NCRA 0.00
- CMMB 0.00
- Stochastic Oscillator
- NCRA 70.00
- CMMB 30.30
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.